CINECA IRIS Institutional Research Information System

BERTOTTI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.916
AS - Asia 14.362
EU - Europa 12.453
SA - Sud America 899
Continente sconosciuto - Info sul continente non disponibili 759
OC - Oceania 350
AF - Africa 185
Totale 46.924
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.205
CN - Cina 7.009
IT - Italia 3.885
SG - Singapore 2.230
GB - Regno Unito 1.537
DE - Germania 1.497
JP - Giappone 1.285
FR - Francia 999
HK - Hong Kong 719
BR - Brasile 667
IN - India 644
ES - Italia 618
FI - Finlandia 605
VN - Vietnam 593
CA - Canada 514
KR - Corea 496
SE - Svezia 494
NL - Olanda 451
IE - Irlanda 430
AU - Australia 276
TW - Taiwan 253
BE - Belgio 236
TR - Turchia 236
CH - Svizzera 234
PL - Polonia 233
AT - Austria 220
UA - Ucraina 150
RU - Federazione Russa 135
ID - Indonesia 127
BD - Bangladesh 120
MX - Messico 110
IL - Israele 109
PT - Portogallo 109
GR - Grecia 106
TH - Thailandia 84
DK - Danimarca 82
AR - Argentina 76
CZ - Repubblica Ceca 74
NZ - Nuova Zelanda 72
RO - Romania 70
IR - Iran 60
NO - Norvegia 59
SA - Arabia Saudita 51
ZA - Sudafrica 51
PK - Pakistan 49
IQ - Iraq 48
MY - Malesia 46
CL - Cile 43
HU - Ungheria 42
CO - Colombia 38
EE - Estonia 30
EG - Egitto 30
EC - Ecuador 28
JO - Giordania 27
LT - Lituania 26
PH - Filippine 21
HR - Croazia 20
JM - Giamaica 20
MA - Marocco 19
UZ - Uzbekistan 18
LB - Libano 17
AM - Armenia 16
TN - Tunisia 16
PE - Perù 15
NP - Nepal 14
SI - Slovenia 14
SK - Slovacchia (Repubblica Slovacca) 14
KE - Kenya 13
NG - Nigeria 13
RS - Serbia 13
SN - Senegal 13
VE - Venezuela 12
CR - Costa Rica 11
MO - Macao, regione amministrativa speciale della Cina 11
BG - Bulgaria 10
KZ - Kazakistan 10
PR - Porto Rico 10
QA - Qatar 10
UY - Uruguay 10
AE - Emirati Arabi Uniti 9
BA - Bosnia-Erzegovina 9
LV - Lettonia 9
DZ - Algeria 8
LK - Sri Lanka 8
TT - Trinidad e Tobago 8
CY - Cipro 7
LU - Lussemburgo 7
AL - Albania 6
AP - ???statistics.table.value.countryCode.AP??? 6
BY - Bielorussia 6
GE - Georgia 6
NI - Nicaragua 6
OM - Oman 6
PY - Paraguay 6
SY - Repubblica araba siriana 6
BH - Bahrain 5
EU - Europa 5
IS - Islanda 5
MT - Malta 5
AZ - Azerbaigian 4
Totale 46.095
Salva come PNG Salva come JPEG
Città #
Singapore 1.357
Beijing 1.262
Ashburn 1.096
Ann Arbor 1.069
Shanghai 946
Chandler 826
Fairfield 798
San Jose 651
Houston 646
Redwood City 487
Cambridge 479
Guangzhou 479
Seattle 461
Turin 452
Milan 440
Tokyo 420
Santa Clara 419
Woodbridge 408
Dublin 390
Wilmington 360
New York 342
Torino 339
Los Angeles 327
Nanjing 274
Helsinki 262
Munich 255
Hong Kong 243
Hangzhou 214
Dallas 188
Rome 186
Boston 174
Seoul 167
The Dalles 167
London 164
Ho Chi Minh City 161
Dearborn 160
Lappeenranta 158
Wuhan 158
Vienna 155
Boardman 153
San Diego 153
Chicago 152
Taipei 149
Pisa 148
Columbus 145
Paris 143
Nyköping 142
Hanoi 134
Naples 131
Amsterdam 129
Warsaw 128
Barcelona 127
Chengdu 125
Hefei 119
Toronto 117
Jacksonville 116
Zhengzhou 110
Villeurbanne 106
San Francisco 105
São Paulo 100
Medford 99
Princeton 99
Lauterbourg 98
Changsha 95
Madrid 93
Frankfurt am Main 92
Manchester 92
Buffalo 91
Jakarta 89
Fremont 83
Atlanta 82
Central 81
Duncan 81
Istanbul 81
Tianjin 81
Berlin 80
Council Bluffs 77
Bengaluru 76
Genoa 75
Philadelphia 75
Shenyang 74
Brussels 73
Ottawa 71
Jinan 69
Mumbai 69
Shenzhen 69
Chongqing 68
Phoenix 68
Central District 64
Sydney 64
Dong Ket 58
Nanchang 56
Nashville 56
Bologna 54
Montreal 54
Melbourne 52
Heidelberg 49
Nuremberg 48
Salt Lake City 48
Florence 47
Totale 23.203
Salva come PNG Salva come JPEG
Nome #
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. 7.407
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 6.281
Adaptive mutability of colorectal cancers in response to targeted therapies 2.631
Stromal contribution to the colorectal cancer transcriptome. 2.196
MET signalling: principles and functions in development, organ regeneration and cancer. 2.017
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.341
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 1.003
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 978
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 977
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 827
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 754
The genomic landscape of response to EGFR blockade in colorectal cancer 563
MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. 503
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 456
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 455
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 453
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer 435
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 409
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 389
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 389
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts 369
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype 367
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 346
Only a subset of Met-activated pathways are required to sustain oncogene addiction 341
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 337
Met-driven invasive growth involves transcriptional regulation of Arhgap12 328
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer 327
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 318
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 317
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 316
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 313
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 311
Inhibition of Src impairs the growth of met-addicted gastric tumors. 306
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 305
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 293
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 287
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 287
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors 265
Effective drug combinations in breast, colon and pancreatic cancer cells 259
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 258
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 256
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 251
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga 249
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS. 237
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 233
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells 231
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 224
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer 224
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 219
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 215
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 214
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 214
Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma 209
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 208
Semalytics: a semantic analytics platform for the exploration of distributed and heterogeneous cancer data in translational research 203
PDX-MI: Minimal information for patient-derived tumor xenograft models 200
One tool to find them all: A case of data integration and querying in a distributed LIMS platform 195
CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system 191
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 191
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases 184
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin 172
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 172
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 171
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 161
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 159
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 156
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 154
DNA demethylation triggers cell free DNA release in colorectal cancer cells 152
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 152
LAS: A Bio-Clinical Integrated Laboratory Information System for Translational Data Management 151
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients 150
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer 148
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. 148
Animal research: Temper Italy's strict lab-animal law. 147
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways 147
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) 146
Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity 143
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models 143
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 139
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 138
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells 138
Met as a potential therapeutic target in basal-like breast cancer 137
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer 126
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. 124
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling 124
The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization 118
Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity 117
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma 116
Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies 115
Tyrosine kinase signal specificity: lessons from the HGF receptor. 107
EGAsubmitter: A software to automate submission of nucleic acid sequencing data to the European Genome-phenome Archive 106
Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer 101
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation 101
PO-050 A molecularly annotated platform of pdx-derived cell lines mirrors the genomic landscape of colorectal cancer 98
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts 98
Interrogating open issues in cancer precision medicine with patient-derived xenografts 97
Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer 96
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer 93
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer 91
MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis 88
Totale 46.302
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.737
article - articoli 0
book - libri 0
conference - conferenze 7.199
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.936
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.708 0 490 466 507 385 390 448 404 405 284 523 406
2022/20234.222 328 340 245 405 325 590 310 397 440 219 306 317
2023/20244.918 381 405 312 432 359 399 407 415 154 534 645 475
2024/20257.059 373 443 501 602 960 595 462 601 754 535 553 680
2025/20269.740 942 543 567 890 1.035 570 1.342 515 947 763 589 1.037
2026/2027966 478 488 0 0 0 0 0 0 0 0 0 0
Totale 46.924